Streamline mRNA Vaccine Development with Rapid Multiplexed Potency Tests

Food fraud is estimated to cost the world economy more than $49 billion per year. The 2013 horse meat scandal alone was reported to cost the UK economy more than £1 billion. The effects of food adulteration reach much further than just these serious economic consequences. The Chinese infant formula scandal, which led to multiple mortalities and hundreds of thousands of babies hospitalized, brought into focus the health implications of economically motivated adulteration. Therefore, stakeholders in the food industry should be stepping up to help eliminate this global problem, not only to protect company brand identity but also to safeguard the well-being of consumers. A key aim of the scientific community should be to arm these stakeholders with the appropriate tools to make economically motivated food adulteration a thing of the past. New approaches are needed to help tackle food adulteration. Traditional targeted methods are failing to keep up with the actions of fraudsters, who are numerous and are active at multiple points throughout the globalized supply chain. There is now a general movement toward non-targeted methodologies to detect food adulteration. Instead of looking for individual components or analytes, non-targeted methods work by taking a much more holistic approach. In many ways the aim is to model normality for a commodity, then look for differences present in a suspect sample that is outside of this normal. In this way, if a fraudster changes what they are using to adulterate with, the analyst will still be able to detect an anomaly.

Biological, chemical and physical contaminants continue to play a significant role in causing human illness and death. While most food supply companies are becoming slowly aware of the breadth of system responsibilities they must assume in terms of preventing food safety problems, many are ineffective due to their lack of how contaminants flow through the supply chain and how to establish procedures to stop such flows from entering or exiting their own doors.

There are approximately 7,000 distinct rare diseases affecting 350 million people worldwide, approximately 80 percent of which are caused by faulty genes. The US Food and Drug Administration (FDA) has more than 700 active Investigational New Drug Applications (INDs) for gene and cell therapies and in 2017, the FDA approved two cell-based gene therapies and it is anticipated that gene therapy will become a mainstay treatment for many rare diseases.

As scientific innovation has led to new trial designs, modern cloud technologies have enabled the industry to better manage how clinical trials are executed. Newer, more advanced cloud applications now offer unified data and process models, allowing organizations to manage their end-to-end clinical trial process within a single system. Rather than juggling individual point solutions, innovative organizations are using a unified clinical platform for greater efficiency, quality, and speed of execution. Join Veeva and Idorsia to learn how your organization can leverage a unified clinical operating model and drive new levels of efficiency across the entire clinical ecosystem.